Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.
The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.
The drug development firm anticipates the phase one trial to start later in the year, as per the filing.
The company climbed past 31% in recent Wednesday trade.
Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.